Reiterate

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Research, Reiterate, Neoplasm, FDA, Cancer, Adium, Disassembler, International Society, NASDAQ Biotechnology Index, Interim, GM-CSF, Self-assembly, NBI, Therapy, Interest, Patient, HITS, Clinical trial, Congress, IND, Human, Cryptocurrency

On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.

Key Points: 
  • On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.
  • The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
  • The Company did not have license revenues in the quarter ended December 31, 2023 and had license revenues of $0.5 million for the year ended December 31, 2023.
  • The net income for the quarter ended December 31, 2022, was after $15.0 million of license revenue recognized in the fourth quarter of 2022.

EQS-News: ADS-TEC Energy Provides Preliminary Financial Results for Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, February 8, 2024
Investment, Growth, Bank statement, EUR, Reiterate, FY

NÜRTINGEN, Germany – February 8, 2024 – ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, today announced preliminary unaudited financial results for the 3 and 12 months ended December 31st, 2023.

Key Points: 
  • NÜRTINGEN, Germany – February 8, 2024 – ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, today announced preliminary unaudited financial results for the 3 and 12 months ended December 31st, 2023.
  • This announcement comes ahead of ADS-TEC Energy’s Full-Year 2023 full financial results, to be announced in late April 2024.
  • The Company experienced its first profitable quarter in Q4 2023, driven by an easing of previous supply chain issues and solid operational performance.
  • Set forth above are certain estimated preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.

ADS-TEC Energy Provides Preliminary Financial Results for Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, February 8, 2024
Alternative Energy, Energy, Batteries, Technology, Other Energy, Investment, Growth, Bank statement, EUR, Reiterate, FY

ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, today announced preliminary unaudited financial results for the 3 and 12 months ended December 31st, 2023.

Key Points: 
  • ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, today announced preliminary unaudited financial results for the 3 and 12 months ended December 31st, 2023.
  • This announcement comes ahead of ADS-TEC Energy’s Full-Year 2023 full financial results, to be announced in late April 2024.
  • The Company experienced its first profitable quarter in Q4 2023, driven by an easing of previous supply chain issues and solid operational performance.
  • Set forth above are certain estimated preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, August 3, 2023
Toxic leukoencephalopathy, Cancer, Neuro, Action, Patient, ACTION, Human, Reiterate, Conference, ONC201, Pharmaceutical industry

DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.6 million, or $0.21 per basic and diluted share, for the second quarter of 2023.
  • Research and development expenses decreased to $16.9 million for the second quarter of 2023, compared to $18.0 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a business update today at 8:30 a.m.

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, May 4, 2023
AACR, University, Reiterate, Glioma, ONC201, Neoplasm, CNO, Survival, NDA, Biomarker, ID, Glioblastoma, Literature, American Association for Cancer Research, Patient, United Kingdom, PNOC, Research, ACTION, Conference, DRD2, Disease, Pharmaceutical industry

DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.
  • Research and development expenses decreased to $18.8 million for the first quarter of 2023, compared to $19.0 million for the same period in 2022.
  • General and administrative expenses increased to $5.7 million for the first quarter of 2023, compared to $5.6 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a business update today at 8:30 a.m.

Ero Copper reports record full-year 2021 operating and financial results

Retrieved on: 
Tuesday, March 8, 2022
MCSA, Public expenditure, Boa, Copper, Company, Gold, El Pilar mine, Deepening, EBITDA, Board, ERO, Board of directors, Tax, Depreciation, NYSE, Royal Gold, GLOBE, TSX, AISC, Growth, Silver, Reiterate, CEO, Security (finance), Cryptocurrency, Renewable energy, Animal, Uranium, Note

VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce its financial results for the three and twelve months ended December 31, 2021. Management will host a conference call tomorrow, Wednesday, March 9, 2022, at 11:30 a.m. Eastern time to discuss the results. Dial-in details for the call can be found near the end of this press release.

Key Points: 
  • (all amounts in US dollars, unless otherwise noted)
    VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) (Ero or the Company) is pleased to announce its financial results for the three and twelve months ended December 31, 2021.
  • Management will host a conference call tomorrow, Wednesday, March 9, 2022, at 11:30 a.m. Eastern time to discuss the results.
  • Commenting on the results, David Strang, CEO, stated, 2021 marked another exceptional year for Ero.
  • C1 cash cost per pound of copper produced are net of by-product credits from metal produced at the MCSA Mining Complex.